Miami.- The Miller School of Medicine at the University of Miami (UM) is seeking around 1,000 healthy adult volunteers to participate in South Florida in a vaccine trial against COVID-19 disease, which produces the new SARS-CoV-2 coronavirus.
According to a statement distributed this Thursday, it is the first Phase 3 clinical trial to be conducted by the National Institutes of Health Prevention Trials Network COVID-19 (CoVPN), for which Miller School has been selected.
The objective is to test the vaccine developed by scientists from the National Institute of Allergy and Infectious Diseases (Niaid), belonging to the National Institutes of Health (NIH), along with their collaborators from the Modern biotechnology company, the statement details.
Miller School plans to begin study this summer with South Florida volunteers, who must be 18 years of age or older and can register to participate on the page. coronaviruspreventionnetwork.org.
WHO: 23 POSSIBLE VACCINES AGAINST COVID-19 ARE TESTED IN HUMANS
“We are committed to involving individuals representing the range of residents affected by COVID-19 in South Florida by gender, age, race, and ethnicity, as well as those who are particularly at risk due to medical conditions,” said the Dr. Susanne Doblecki-Lewis, expert in infectious diseases and director of the project.
“The COVID-19 pandemic is having a tremendous impact in South Florida and around the world, so we are testing vaccines with the goal of finding a safe and effective way to stop the spread of the virus,” added Doblecki- Lewis.
According to the statement, Miller School is a leading research center for infectious diseases, particularly HIV and AIDS, and its affiliation with the HIV Vaccine Trials Network made it “a natural place to discuss vaccines against COVID-19 ».
For its part, Moderna expects to produce between 500 and 1,000 million doses of its mRNA-1273 vaccine against COVID-19, which, according to the company, has shown positive results in the first phase of clinical tests.
Moderna assured this Wednesday that once the three phases of clinical tests have been completed and regulatory approval has been obtained, they will be able to produce doses from their associated laboratories in the US and Spain to supply the main global markets.
Phase 3, final to know if the Moderna vaccine will obtain approval to be distributed, will begin on July 27 with 30,000 volunteers chosen at random, but linked to regions where the new coronavirus has hit hardest.
Florida this Thursday set a new daily record of deaths due to COVID-19, with 156 in the last 24 hours, for a total of 4,782 deaths of the nearly 316,000 confirmed cases in that state since March 1.